A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: Mitomycin chemotherapy vs BCG immunotherapy

Archivio Italiano di Urologia e Andrologia

Volumn 80, Issue 4, 2008, Pages 167-171

  Mangiarotti, Barbara ^a,c   Trinchieri, Alberto ^b   Del Nero, Alberto ^a,c   Montanari, Emanuele ^a,c  

^a SAN PAOLO HOSPITAL   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemotherapy; Immunotherapy; Non muscle invasive bladder cancer; Superficial bladder tumour, recurrence

Indexed keywords

BCG VACCINE; MITOMYCIN C; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INVASION; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; CYSTITIS; DISEASE FREE SURVIVAL; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INSTILLATION; DRUG WITHDRAWAL; EPIDIDYMITIS; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE TUMOR; MYALGIA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT CANCER;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 58849140494     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes A, Buffioux C, Denis L, Newling D, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-477
2. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol (1985) 134:40-47
3. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am (1992); 19:573-580
4. Lamm DL. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol 1995; 27 (suppl l):2-8
5. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA Jr, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer R Grossman HB. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder: a Southwest Oncology Group Study. Urol Oncol (1995); 1:119-126
6. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol (2002); 168:1964-1970
7. Bohle A, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology (2004); 63:682-687
8. Huncharek M, Geschwind ]-F, Witherspoon B, Mc Garry R, Adcock D: Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 37° 3 patients from 11 randomised trials. J Clin Epidemiol (2000); 53:676-680
9. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Mejden A, Parkmar MK, Bijnens L. A combined analysis of European Organisation for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for prophylactic treatment of Ta T1 bladder cancer. European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer. J Urol 1996; 156:1934-1941
10. Han RE Pan ]G: Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer. A meta-analysis of randomized trials. Urology 2006; 67:1216-1223